| dc.contributor.author | Flygare, Johan | |
| dc.contributor.author | Wong, Bill | |
| dc.coverage.temporal | Fall 2009 | |
| dc.date.accessioned | 2023-03-06T17:31:06Z | |
| dc.date.available | 2023-03-06T17:31:06Z | |
| dc.date.issued | 2009-12 | |
| dc.identifier | 7.341-Fall2009 | |
| dc.identifier.other | 7.341 | |
| dc.identifier.other | IMSCP-MD5-e7749bc6b8079c335015707858b81d06 | |
| dc.identifier.uri | https://hdl.handle.net/1721.1/148359 | |
| dc.description.abstract | Where do new drugs and treatments come from? This class will take you from the test tubes and mice of the laboratory to the treatment of patients with deadly blood disorders. Students will learn how to think as a scientist through discussion of primary research papers describing the discoveries of several novel treatments. Topics such as gene therapy, the potential of drugs based on RNA interference and the reprogramming of somatic cells into stem cells for regenerative medicine will be discussed. This course is one of many Advanced Undergraduate Seminars offered by the Biology Department at MIT. These seminars are tailored for students with an interest in using primary research literature to discuss and learn about current biological research in a highly interactive setting. Many instructors of the Advanced Undergraduate Seminars are postdoctoral scientists with a strong interest in teaching. | en |
| dc.language.iso | en-US | |
| dc.rights | This site (c) Massachusetts Institute of Technology 2023. Content within individual courses is (c) by the individual authors unless otherwise noted. The Massachusetts Institute of Technology is providing this Work (as defined below) under the terms of this Creative Commons public license ("CCPL" or "license") unless otherwise noted. The Work is protected by copyright and/or other applicable law. Any use of the work other than as authorized under this license is prohibited. By exercising any of the rights to the Work provided here, You (as defined below) accept and agree to be bound by the terms of this license. The Licensor, the Massachusetts Institute of Technology, grants You the rights contained here in consideration of Your acceptance of such terms and conditions. | en |
| dc.rights | Attribution-NonCommercial-ShareAlike 3.0 Unported | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/ | * |
| dc.subject | molecularly targeted therapy | en |
| dc.subject | blood disorders | en |
| dc.subject | chronic myelogenous leukemia | en |
| dc.subject | CML | en |
| dc.subject | Gleevec | en |
| dc.subject | chromosomal translocation | en |
| dc.subject | stem cells | en |
| dc.subject | blood cells | en |
| dc.subject | hematopoiesis | en |
| dc.subject | hematopoieteic stem cell | en |
| dc.subject | genetic disorder | en |
| dc.subject | Leukemia | en |
| dc.title | 7.341 Bench to Bedside: Molecularly Targeted Therapies in Blood Disorders and Malignancy, Fall 2009 | en |
| dc.title.alternative | Bench to Bedside: Molecularly Targeted Therapies in Blood Disorders and Malignancy | en |
| dc.type | Learning Object | |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | |
| dc.audience.educationlevel | Undergraduate | |
| dc.subject.cip | 511010 | en |
| dc.subject.cip | Cytogenetics/Genetics/Clinical Genetics Technology/Technologist | en |
| dc.date.updated | 2023-03-06T17:31:12Z | |
